Physician profile
Auda Auda
NPI 1780280875
$1,593.44
in general payments reported to CMS, 2019-2025
24 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $88.06 · 2024: $715 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $204.17 | 2024-2025 | Breztri, Airsupra |
| Intra-Sana Laboratories | $179.66 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Viiv Healthcare Company | $170.03 | 2025 | Apretude |
| Painteq LLC | $148.03 | 2024 | Painteq |
| Ardelyx, INC. | $121.84 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.07 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $100.91 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $84.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $75.93 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $56.19 | 2025 | Wegovy, Ozempic |
| Hologic Sales and Service, LLC | $54.47 | 2024-2025 | Aptima |
| Glaxosmithkline, LLC. | $46.21 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $25.12 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $24.69 | 2025 | Neffy |
| Philips North America LLC | $23.61 | 2025 | Ecc Solutions |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $23.33 | 2024 | Inspire |
| Abbott Laboratories | $20.52 | 2024 | Freestyle Libre 3 |
| Phadia US INC. | $19.95 | 2025 | Immunocap |
| Topcon Healthcare, INC. | $19.18 | 2024 | |
| Echosens North America, INC. | $18.72 | 2025 | Fibroscan |
| Currax Pharmaceuticals LLC | $16.83 | 2025 | Contrave |
| Paratek Pharmaceuticals, INC. | $14.49 | 2023 | Nuzyra |
| Cranial Technologies, INC | $13.11 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $12.75 | 2023 | Vaxneuvance, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Auda Auda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.